Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in
both men and women worldwide. This is in spite of widespread, effective measures of …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many
new treatment methods have been developed during recent decades. The Japanese …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest
number of deaths from malignant neoplasms among women and the third largest number …

Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …

Fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years,
increased understanding of the mechanism of action of 5-FU has led to the development of …